| 1 | Mode of progression in smoldering multiple myeloma: a study of 406 patients | 7.9 | 21 | Citations (PDF) |
| 2 | Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis | 7.9 | 20 | Citations (PDF) |
| 3 | Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide | 7.9 | 5 | Citations (PDF) |
| 4 | Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma | 6.1 | 7 | Citations (PDF) |
| 5 | Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management | 6.1 | 285 | Citations (PDF) |
| 6 | Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma | 7.9 | 13 | Citations (PDF) |
| 7 | Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm | 7.9 | 12 | Citations (PDF) |
| 8 | Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14) | 10.4 | 0 | Citations (PDF) |
| 9 | Risk factors for severe infection and mortality In patients with <scp>COVID</scp>‐19 in patients with multiple myeloma and <scp>AL</scp> amyloidosis | 6.1 | 22 | Citations (PDF) |
| 10 | Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival | 6.1 | 15 | Citations (PDF) |
| 11 | A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma | 7.9 | 2 | Citations (PDF) |
| 12 | Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience | 6.1 | 8 | Citations (PDF) |
| 13 | Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study | 1.0 | 4 | Citations (PDF) |
| 14 | Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance | 7.9 | 3 | Citations (PDF) |
| 15 | Multiple myeloma with acute light chain cast nephropathy | 7.9 | 44 | Citations (PDF) |
| 16 | A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (<scp>CARAMEL</scp>) | 6.1 | 1 | Citations (PDF) |
| 17 | Conditional survival in multiple myeloma and impact of prognostic factors over time | 7.9 | 19 | Citations (PDF) |
| 18 | Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma | 6.1 | 43 | Citations (PDF) |
| 19 | Muscle and fat composition in patients with newly diagnosed multiple myeloma | 7.9 | 12 | Citations (PDF) |
| 20 | Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)–Associated Lesions: A Case Series | 1.4 | 25 | Citations (PDF) |
| 21 | Mortality trends in multiple myeloma after the introduction of novel therapies in the United States | 10.4 | 90 | Citations (PDF) |
| 22 | Prognostic significance of acquired 1q22 gain in multiple myeloma | 6.1 | 8 | Citations (PDF) |
| 23 | Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients | 6.1 | 10 | Citations (PDF) |
| 24 | Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome | 6.1 | 12 | Citations (PDF) |
| 25 | Kidney Transplant Outcomes of Patients With Multiple Myeloma | 2.5 | 21 | Citations (PDF) |
| 26 | A simple additive staging system for newly diagnosed multiple myeloma | 7.9 | 80 | Citations (PDF) |
| 27 | Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation | 6.1 | 4 | Citations (PDF) |
| 28 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group | 9.2 | 145 | Citations (PDF) |
| 29 | Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma | 5.1 | 25 | Citations (PDF) |
| 30 | Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method | 5.1 | 7 | Citations (PDF) |
| 31 | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota | 7.9 | 30 | Citations (PDF) |
| 32 | Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant | 2.0 | 56 | Citations (PDF) |
| 33 | Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells | 2.7 | 9 | Citations (PDF) |
| 34 | Multiple myeloma: 2022 update on diagnosis, risk stratification, and management | 6.1 | 640 | Citations (PDF) |
| 35 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | 10.4 | 2,949 | Citations (PDF) |
| 36 | Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome | 4.1 | 1 | Citations (PDF) |
| 37 | Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? | 1.2 | 3 | Citations (PDF) |
| 38 | Smoldering multiple myeloma current treatment algorithms | 7.9 | 58 | Citations (PDF) |
| 39 | Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | 7.9 | 8 | Citations (PDF) |
| 40 | Monoclonal Gammopathy of Undetermined Significance | 10.4 | 31 | Citations (PDF) |
| 41 | Characterization and prognostic implication of delayed complete response in AL amyloidosis | 1.9 | 6 | Citations (PDF) |
| 42 | Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide | 1.9 | 6 | Citations (PDF) |
| 43 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study | 26.0 | 61 | Citations (PDF) |
| 44 | Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as first‐line therapy in multiple myeloma | 6.1 | 21 | Citations (PDF) |
| 45 | Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial | 9.2 | 115 | Citations (PDF) |
| 46 | Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients | 10.4 | 13 | Citations (PDF) |
| 47 | Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS) | 7.9 | 22 | Citations (PDF) |
| 48 | Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report | 7.9 | 146 | Citations (PDF) |
| 49 | Prognostic restaging after treatment initiation in patients with AL amyloidosis | 5.1 | 14 | Citations (PDF) |
| 50 | Coagulation Abnormalities in Light Chain Amyloidosis | 3.1 | 19 | Citations (PDF) |
| 51 | Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits | 0.4 | 68 | Citations (PDF) |
| 52 | Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaBlood, 2021, 137, 3616-3628 | 4.2 | 88 | Citations (PDF) |
| 53 | Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy | 3.1 | 35 | Citations (PDF) |
| 54 | MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients | 7.9 | 40 | Citations (PDF) |
| 55 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group | 26.0 | 222 | Citations (PDF) |
| 56 | Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review | 6.1 | 22 | Citations (PDF) |
| 57 | Assessment of fixed‐duration therapies for treatment‐naïve <scp>Waldenström</scp> macroglobulinemia | 6.1 | 24 | Citations (PDF) |
| 58 | Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update | 3.1 | 66 | Citations (PDF) |
| 59 | Sequencing of myeloma therapy: Finding the right path among many standards | 2.2 | 10 | Citations (PDF) |
| 60 | Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients | 7.9 | 41 | Citations (PDF) |
| 61 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center | 1.0 | 16 | Citations (PDF) |
| 62 | Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis | 2.0 | 5 | Citations (PDF) |
| 63 | Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma | 5.1 | 18 | Citations (PDF) |
| 64 | Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis | 1.5 | 3 | Citations (PDF) |
| 65 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials | 6.1 | 30 | Citations (PDF) |
| 66 | The Prognostic Role of <i>MYC</i> Structural Variants Identified by NGS and FISH in Multiple Myeloma | 6.9 | 30 | Citations (PDF) |
| 67 | Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia | 2.4 | 26 | Citations (PDF) |
| 68 | The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM) | 7.9 | 16 | Citations (PDF) |
| 69 | Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort | 6.1 | 12 | Citations (PDF) |
| 70 | Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis | 7.9 | 23 | Citations (PDF) |
| 71 | Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis | 10.4 | 7 | Citations (PDF) |
| 72 | Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage | 7.9 | 150 | Citations (PDF) |
| 73 | “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience | 7.9 | 44 | Citations (PDF) |
| 74 | Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis | 4.7 | 30 | Citations (PDF) |
| 75 | Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma | 21.6 | 245 | Citations (PDF) |
| 76 | Community-Based Study of Celiac Disease Autoimmunity Progression in Adults | 1.0 | 26 | Citations (PDF) |
| 77 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients | 6.1 | 18 | Citations (PDF) |
| 78 | Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy | 1.0 | 12 | Citations (PDF) |
| 79 | Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis | 4.1 | 42 | Citations (PDF) |
| 80 | Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells | 6.1 | 55 | Citations (PDF) |
| 81 | Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia | 6.1 | 49 | Citations (PDF) |
| 82 | Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma | 14.6 | 14 | Citations (PDF) |
| 83 | Multiple myeloma current treatment algorithms | 7.9 | 298 | Citations (PDF) |
| 84 | Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma | 6.9 | 51 | Citations (PDF) |
| 85 | International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) | 7.9 | 239 | Citations (PDF) |
| 86 | Predictors of short-term survival in Waldenström Macroglobulinemia | 1.5 | 5 | Citations (PDF) |
| 87 | Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio | 6.1 | 23 | Citations (PDF) |
| 88 | Treatments for newly diagnosed multiple myeloma: when endurance is interrupted – Authors' reply | 26.0 | 0 | Citations (PDF) |
| 89 | Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities | 5.1 | 90 | Citations (PDF) |
| 90 | Clinical Trial End Points in Severe COVID-19 | 3.1 | 2 | Citations (PDF) |
| 91 | In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma | 7.9 | 13 | Citations (PDF) |
| 92 | Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response | 7.9 | 104 | Citations (PDF) |
| 93 | Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial | 26.0 | 223 | Citations (PDF) |
| 94 | Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma | 7.9 | 22 | Citations (PDF) |
| 95 | Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients | 7.9 | 17 | Citations (PDF) |
| 96 | The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? | 7.9 | 15 | Citations (PDF) |
| 97 | BiTEing the Tumor | 21.6 | 8 | Citations (PDF) |
| 98 | Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) | 7.9 | 203 | Citations (PDF) |
| 99 | Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis | 3.3 | 9 | Citations (PDF) |
| 100 | c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma | 1.9 | 9 | Citations (PDF) |
| 101 | Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management | 6.1 | 693 | Citations (PDF) |
| 102 | Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia | 6.1 | 17 | Citations (PDF) |
| 103 | Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma | 1.5 | 6 | Citations (PDF) |
| 104 | Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance | 5.1 | 23 | Citations (PDF) |
| 105 | Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis | 7.9 | 35 | Citations (PDF) |
| 106 | Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis | 7.9 | 21 | Citations (PDF) |
| 107 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis | 6.1 | 47 | Citations (PDF) |
| 108 | Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients | 1.0 | 28 | Citations (PDF) |
| 109 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma | 10.4 | 18 | Citations (PDF) |
| 110 | The Case for Masks | 3.1 | 1 | Citations (PDF) |
| 111 | Utility of serum free light chain ratio in response definition in patients with multiple myeloma | 5.1 | 8 | Citations (PDF) |
| 112 | A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis | 7.9 | 34 | Citations (PDF) |
| 113 | Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma | 5.1 | 29 | Citations (PDF) |
| 114 | The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma | 4.2 | 0 | Citations (PDF) |
| 115 | Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma | 6.1 | 20 | Citations (PDF) |
| 116 | Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis | 7.9 | 12 | Citations (PDF) |
| 117 | Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern | 2.4 | 56 | Citations (PDF) |
| 118 | Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria | 4.7 | 13 | Citations (PDF) |
| 119 | Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis | 5.1 | 8 | Citations (PDF) |
| 120 | Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis | 4.1 | 10 | Citations (PDF) |
| 121 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study | 52.8 | 569 | Citations (PDF) |
| 122 | Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance | 10.4 | 47 | Citations (PDF) |
| 123 | Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma | 6.1 | 22 | Citations (PDF) |
| 124 | Smoldering Multiple Myeloma | 1.8 | 18 | Citations (PDF) |
| 125 | International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders | 26.0 | 426 | Citations (PDF) |
| 126 | Multiple myeloma: Every year a new standard? | 2.2 | 216 | Citations (PDF) |
| 127 | Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies | 7.9 | 15 | Citations (PDF) |
| 128 | Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma | 1.5 | 8 | Citations (PDF) |
| 129 | Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis | 2.4 | 18 | Citations (PDF) |
| 130 | Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma | 4.1 | 29 | Citations (PDF) |
| 131 | Natural history of multiple myeloma with de novo del(17p) | 7.9 | 54 | Citations (PDF) |
| 132 | Two types of amyloidosis presenting in a single patient: a case series | 7.9 | 70 | Citations (PDF) |
| 133 | Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy | 6.1 | 19 | Citations (PDF) |
| 134 | Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015 | 3.1 | 132 | Citations (PDF) |
| 135 | Substratification of patients with newly diagnosed standard‐risk multiple myeloma | 2.4 | 14 | Citations (PDF) |
| 136 | Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial | 1.6 | 4 | Citations (PDF) |
| 137 | Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis | 10.4 | 10 | Citations (PDF) |
| 138 | The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) | 7.9 | 93 | Citations (PDF) |
| 139 | Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis | 6.1 | 21 | Citations (PDF) |
| 140 | Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma | 10.4 | 21 | Citations (PDF) |
| 141 | A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing | 3.1 | 71 | Citations (PDF) |
| 142 | Impact of acquired del(17p) in multiple myeloma | 5.1 | 53 | Citations (PDF) |
| 143 | Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma | 5.1 | 32 | Citations (PDF) |
| 144 | Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma | 7.9 | 33 | Citations (PDF) |
| 145 | Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement | 7.9 | 86 | Citations (PDF) |
| 146 | Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timingBlood, 2019, 133, 652-659 | 4.2 | 47 | Citations (PDF) |
| 147 | Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method | 6.1 | 14 | Citations (PDF) |
| 148 | Molecular signatures of multiple myeloma progression through single cell RNA-Seq | 7.9 | 87 | Citations (PDF) |
| 149 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial | 52.8 | 219 | Citations (PDF) |
| 150 | IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features | 10.4 | 49 | Citations (PDF) |
| 151 | Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis | 10.4 | 37 | Citations (PDF) |
| 152 | Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis | 10.4 | 12 | Citations (PDF) |
| 153 | Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria | 10.4 | 101 | Citations (PDF) |
| 154 | Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review | 3.1 | 37 | Citations (PDF) |
| 155 | The multiple myelomas — current concepts in cytogenetic classification and therapy | 75.5 | 270 | Citations (PDF) |
| 156 | Time to plateau as a predictor of survival in newly diagnosed multiple myeloma | 6.1 | 16 | Citations (PDF) |
| 157 | Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma | 1.6 | 23 | Citations (PDF) |
| 158 | Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia | 1.5 | 87 | Citations (PDF) |
| 159 | Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance | 10.4 | 33 | Citations (PDF) |
| 160 | The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response | 10.4 | 13 | Citations (PDF) |
| 161 | Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance | 43.7 | 569 | Citations (PDF) |
| 162 | Reply to Castillo et al. | 6.1 | 3 | Citations (PDF) |
| 163 | Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? | 4.7 | 75 | Citations (PDF) |
| 164 | Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies | 7.9 | 114 | Citations (PDF) |
| 165 | Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma | 6.1 | 62 | Citations (PDF) |
| 166 | <i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia | 6.1 | 68 | Citations (PDF) |
| 167 | Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL) | 6.1 | 11 | Citations (PDF) |
| 168 | Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature | 1.0 | 6 | Citations (PDF) |
| 169 | How I manage monoclonal gammopathy of undetermined significanceBlood, 2018, 131, 163-173 | 4.2 | 119 | Citations (PDF) |
| 170 | Value and Cost of Myeloma Therapy | 4.6 | 72 | Citations (PDF) |
| 171 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma | 7.9 | 17 | Citations (PDF) |
| 172 | Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | 7.9 | 104 | Citations (PDF) |
| 173 | Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma | 7.9 | 90 | Citations (PDF) |
| 174 | Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome | 7.9 | 34 | Citations (PDF) |
| 175 | Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group | 7.9 | 75 | Citations (PDF) |
| 176 | Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry | 7.9 | 60 | Citations (PDF) |
| 177 | Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study | 7.9 | 22 | Citations (PDF) |
| 178 | Utility and prognostic value of <sup>18</sup>F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma | 6.1 | 24 | Citations (PDF) |
| 179 | Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma | 5.1 | 29 | Citations (PDF) |
| 180 | Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma | 7.9 | 20 | Citations (PDF) |
| 181 | Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials | 7.9 | 80 | Citations (PDF) |
| 182 | Serum free light chain measurements to reduce 24‐h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein | 6.1 | 7 | Citations (PDF) |
| 183 | Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis | 3.3 | 71 | Citations (PDF) |
| 184 | Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia | 6.1 | 38 | Citations (PDF) |
| 185 | Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management | 6.1 | 189 | Citations (PDF) |
| 186 | Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders | 4.4 | 65 | Citations (PDF) |
| 187 | Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria | 7.9 | 248 | Citations (PDF) |
| 188 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement | 3.3 | 103 | Citations (PDF) |
| 189 | Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics | 10.4 | 13 | Citations (PDF) |
| 190 | Primary systemic amyloidosis in patients with Waldenström macroglobulinemia | 10.4 | 34 | Citations (PDF) |
| 191 | Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse | 10.4 | 27 | Citations (PDF) |
| 192 | Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio | 10.4 | 45 | Citations (PDF) |
| 193 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk | 3.3 | 41 | Citations (PDF) |
| 194 | Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma | 1.7 | 4 | Citations (PDF) |
| 195 | Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition | 4.1 | 69 | Citations (PDF) |
| 196 | Hematology patient reported symptom screen to assess quality of life for AL amyloidosis | 6.1 | 21 | Citations (PDF) |
| 197 | Call for Papers on Clinical Practice Guidelines | 3.1 | 0 | Citations (PDF) |
| 198 | The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment | 4.2 | 52 | Citations (PDF) |
| 199 | Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathBlood, 2017, 129, 2111-2119 | 4.2 | 298 | Citations (PDF) |
| 200 | Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature | 1.6 | 14 | Citations (PDF) |
| 201 | Monoclonal Gammopathy–Associated Peripheral Neuropathy: Diagnosis and Management | 3.1 | 134 | Citations (PDF) |
| 202 | Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis | 4.7 | 6 | Citations (PDF) |
| 203 | Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival | 4.7 | 4 | Citations (PDF) |
| 204 | Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis | 7.6 | 19 | Citations (PDF) |
| 205 | Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma | 2.4 | 23 | Citations (PDF) |
| 206 | The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma | 6.1 | 10 | Citations (PDF) |
| 207 | Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia | 6.1 | 98 | Citations (PDF) |
| 208 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | 26.0 | 486 | Citations (PDF) |
| 209 | Therapy for Relapsed Multiple Myeloma | 3.1 | 134 | Citations (PDF) |
| 210 | Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis | 6.1 | 27 | Citations (PDF) |
| 211 | Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial | 52.8 | 831 | Citations (PDF) |
| 212 | Diagnosis and Management of Waldenström Macroglobulinemia | 14.6 | 125 | Citations (PDF) |
| 213 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsBlood, 2017, 130, 2610-2618 | 4.2 | 109 | Citations (PDF) |
| 214 | Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosisBlood, 2017, 130, 1578-1584 | 4.2 | 21 | Citations (PDF) |
| 215 | Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation | 2.4 | 19 | Citations (PDF) |
| 216 | Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia | 2.4 | 31 | Citations (PDF) |
| 217 | Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials | 6.1 | 26 | Citations (PDF) |
| 218 | Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis | 4.7 | 5 | Citations (PDF) |
| 219 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaBlood, 2017, 130, 1198-1204 | 4.2 | 61 | Citations (PDF) |
| 220 | Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors | 6.1 | 30 | Citations (PDF) |
| 221 | Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation | 6.1 | 49 | Citations (PDF) |
| 222 | Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis | 3.1 | 90 | Citations (PDF) |
| 223 | Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis | 3.3 | 4 | Citations (PDF) |
| 224 | Updated Diagnostic Criteria and Staging System for Multiple Myeloma | 4.6 | 270 | Citations (PDF) |
| 225 | Spectrum of manifestations of monoclonal gammopathy-associated renal lesions | 2.3 | 68 | Citations (PDF) |
| 226 | From the Guest Editor | 1.8 | 0 | Citations (PDF) |
| 227 | Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light‐chain amyloidosis | 4.1 | 40 | Citations (PDF) |
| 228 | Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation | 6.1 | 49 | Citations (PDF) |
| 229 | Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III | 2.4 | 20 | Citations (PDF) |
| 230 | Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibBlood, 2016, 128, 2415-2422 | 4.2 | 54 | Citations (PDF) |
| 231 | Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type | 4.1 | 10 | Citations (PDF) |
| 232 | The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma | 0.7 | 30 | Citations (PDF) |
| 233 | Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies | 1.0 | 24 | Citations (PDF) |
| 234 | Drug Approvals in Oncology: Striking the Right Balance Between Saving Lives and Patient Safety | 3.1 | 1 | Citations (PDF) |
| 235 | A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci | 1.2 | 24 | Citations (PDF) |
| 236 | Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome | 3.1 | 56 | Citations (PDF) |
| 237 | Long‐term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience | 6.1 | 73 | Citations (PDF) |
| 238 | Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management | 6.1 | 409 | Citations (PDF) |
| 239 | Myeloma today: Disease definitions and treatment advances | 6.1 | 152 | Citations (PDF) |
| 240 | N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma | 6.1 | 96 | Citations (PDF) |
| 241 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | 26.0 | 2,576 | Citations (PDF) |
| 242 | Treatment of newly diagnosed myeloma: Bortezomib-based triplet | 1.9 | 9 | Citations (PDF) |
| 243 | Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM) | 1.6 | 1 | Citations (PDF) |
| 244 | Clinical characteristics and outcomes in biclonal gammopathies | 6.1 | 35 | Citations (PDF) |
| 245 | The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation | 0.8 | 29 | Citations (PDF) |
| 246 | Multiple Myeloma: Diagnosis and Treatment | 3.1 | 494 | Citations (PDF) |
| 247 | Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical TrialsBlood, 2016, 128, 1192-1192 | 4.2 | 2 | Citations (PDF) |
| 248 | Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain AmyloidosisBlood, 2016, 128, 2082-2082 | 4.2 | 1 | Citations (PDF) |
| 249 | Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2016, 128, 243-243 | 4.2 | 3 | Citations (PDF) |
| 250 | Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM)Blood, 2016, 128, 2968-2968 | 4.2 | 4 | Citations (PDF) |
| 251 | Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom MacroglobulinemiaBlood, 2016, 128, 2972-2972 | 4.2 | 2 | Citations (PDF) |
| 252 | Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at DiagnosisBlood, 2016, 128, 3272-3272 | 4.2 | 1 | Citations (PDF) |
| 253 | Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain AmyloidosisBlood, 2016, 128, 3317-3317 | 4.2 | 3 | Citations (PDF) |
| 254 | Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World SettingBlood, 2016, 128, 3337-3337 | 4.2 | 5 | Citations (PDF) |
| 255 | Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL AmyloidosisBlood, 2016, 128, 3444-3444 | 4.2 | 1 | Citations (PDF) |
| 256 | Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working GroupBlood, 2016, 128, 4468-4468 | 4.2 | 13 | Citations (PDF) |
| 257 | Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo StageBlood, 2016, 128, 4627-4627 | 4.2 | 2 | Citations (PDF) |
| 258 | Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma | 1.7 | 23 | Citations (PDF) |
| 259 | Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic SubtypeBlood, 2016, 128, 4425-4425 | 4.2 | 0 | Citations (PDF) |
| 260 | Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom MacroglobulinemiaBlood, 2016, 128, 2960-2960 | 4.2 | 15 | Citations (PDF) |
| 261 | Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple MyelomaBlood, 2016, 128, 5615-5615 | 4.2 | 0 | Citations (PDF) |
| 262 | Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease BurdenBlood, 2016, 128, 3273-3273 | 4.2 | 0 | Citations (PDF) |
| 263 | Changes in Uninvolved Immunoglobulins during Multiple Myeloma TherapyBlood, 2016, 128, 3251-3251 | 4.2 | 0 | Citations (PDF) |
| 264 | Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of ExperienceBlood, 2016, 128, 1810-1810 | 4.2 | 0 | Citations (PDF) |
| 265 | Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective EvaluationBlood, 2016, 128, 3306-3306 | 4.2 | 0 | Citations (PDF) |
| 266 | The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple MyelomaBlood, 2016, 128, 1194-1194 | 4.2 | 0 | Citations (PDF) |
| 267 | Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment CategoryBlood, 2016, 128, 3269-3269 | 4.2 | 0 | Citations (PDF) |
| 268 | Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain AmyloidosisBlood, 2016, 128, 3338-3338 | 4.2 | 0 | Citations (PDF) |
| 269 | Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel AgentsBlood, 2016, 128, 3255-3255 | 4.2 | 0 | Citations (PDF) |
| 270 | Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control StudyBlood, 2016, 128, 5576-5576 | 4.2 | 2 | Citations (PDF) |
| 271 | Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog StudyBlood, 2016, 128, 5712-5712 | 4.2 | 0 | Citations (PDF) |
| 272 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaBlood, 2015, 126, 1294-1301 | 4.2 | 85 | Citations (PDF) |
| 273 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015, 125, 2068-2074 | 4.2 | 699 | Citations (PDF) |
| 274 | Macro-QuestBlood, 2015, 125, 2318-2319 | 4.2 | 3 | Citations (PDF) |
| 275 | Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma | 6.1 | 20 | Citations (PDF) |
| 276 | Outcomes of primary refractory multiple myeloma and the impact of novel therapies | 6.1 | 42 | Citations (PDF) |
| 277 | Evolving diagnostic criteria for multiple myeloma | 2.9 | 56 | Citations (PDF) |
| 278 | Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis | 2.4 | 23 | Citations (PDF) |
| 279 | Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis | 6.1 | 85 | Citations (PDF) |
| 280 | Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays | 1.1 | 64 | Citations (PDF) |
| 281 | Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement | 21.6 | 370 | Citations (PDF) |
| 282 | Clinical course and prognosis of non‐secretory multiple myeloma | 1.9 | 70 | Citations (PDF) |
| 283 | Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012 | 0.7 | 112 | Citations (PDF) |
| 284 | Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits | 3.1 | 113 | Citations (PDF) |
| 285 | Treatment of Immunoglobulin Light Chain Amyloidosis | 3.1 | 113 | Citations (PDF) |
| 286 | Bortezomib-induced acute interstitial nephritis | 0.8 | 31 | Citations (PDF) |
| 287 | Smoldering multiple myelomaBlood, 2015, 125, 3069-3075 | 4.2 | 259 | Citations (PDF) |
| 288 | Soluble suppression of tumorigenicity 2 (s<scp>ST</scp>2), but not galactin‐3, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp>‐pro<scp>BNP</scp> and troponin <scp>T</scp> | 6.1 | 40 | Citations (PDF) |
| 289 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | 43.7 | 1,266 | Citations (PDF) |
| 290 | Multiple myeloma after kidney transplantation | 1.7 | 18 | Citations (PDF) |
| 291 | In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)Blood, 2015, 126, 1774-1774 | 4.2 | 6 | Citations (PDF) |
| 292 | Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment OutcomesBlood, 2015, 126, 1830-1830 | 4.2 | 1 | Citations (PDF) |
| 293 | Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 | 4.2 | 47 | Citations (PDF) |
| 294 | Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to BortezomibBlood, 2015, 126, 3050-3050 | 4.2 | 8 | Citations (PDF) |
| 295 | Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell TransplantBlood, 2015, 126, 3177-3177 | 4.2 | 4 | Citations (PDF) |
| 296 | Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic ExperienceBlood, 2015, 126, 4197-4197 | 4.2 | 5 | Citations (PDF) |
| 297 | Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) TrialBlood, 2015, 126, 730-730 | 4.2 | 15 | Citations (PDF) |
| 298 | Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-upBlood, 2015, 126, 3174-3174 | 4.2 | 0 | Citations (PDF) |
| 299 | Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma TumorsBlood, 2015, 126, 4249-4249 | 4.2 | 1 | Citations (PDF) |
| 300 | N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)Blood, 2015, 126, 3292-3292 | 4.2 | 0 | Citations (PDF) |
| 301 | AL Amyloidosis and Patient Reported Quality of LifeBlood, 2015, 126, 3317-3317 | 4.2 | 0 | Citations (PDF) |
| 302 | Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple MyelomaBlood, 2015, 126, 4176-4176 | 4.2 | 0 | Citations (PDF) |
| 303 | Natural History of Amyloidosis Isolated to Fat and Bone Marrow AspirateBlood, 2015, 126, 5303-5303 | 4.2 | 0 | Citations (PDF) |
| 304 | Long‐term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy | 6.1 | 5 | Citations (PDF) |
| 305 | Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias | 6.1 | 38 | Citations (PDF) |
| 306 | Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies | 17.1 | 3 | Citations (PDF) |
| 307 | International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation | 21.6 | 373 | Citations (PDF) |
| 308 | Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant | 1.9 | 23 | Citations (PDF) |
| 309 | Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management | 6.1 | 157 | Citations (PDF) |
| 310 | Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001 | 0.7 | 13 | Citations (PDF) |
| 311 | Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study | 9.2 | 49 | Citations (PDF) |
| 312 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | 26.0 | 4,298 | Citations (PDF) |
| 313 | Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma | 2.3 | 41 | Citations (PDF) |
| 314 | The clinical significance of cereblon expression in multiple myeloma | 0.7 | 99 | Citations (PDF) |
| 315 | Trends in survival of patients with primary plasma cell leukemia: a population-based analysisBlood, 2014, 124, 907-912 | 4.2 | 131 | Citations (PDF) |
| 316 | Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted SequencingBlood, 2014, 124, 169-169 | 4.2 | 3 | Citations (PDF) |
| 317 | Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple MyelomaBlood, 2014, 124, 2053-2053 | 4.2 | 1 | Citations (PDF) |
| 318 | Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)Blood, 2014, 124, 304-304 | 4.2 | 25 | Citations (PDF) |
| 319 | PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple MyelomaBlood, 2014, 124, 3382-3382 | 4.2 | 4 | Citations (PDF) |
| 320 | SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)Blood, 2014, 124, 4762-4762 | 4.2 | 4 | Citations (PDF) |
| 321 | Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study | 4.2 | 15 | Citations (PDF) |
| 322 | Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance TherapyBlood, 2014, 124, 3456-3456 | 4.2 | 0 | Citations (PDF) |
| 323 | Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg DosesBlood, 2014, 124, 4780-4780 | 4.2 | 0 | Citations (PDF) |
| 324 | Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) PatientsBlood, 2014, 124, 4751-4751 | 4.2 | 0 | Citations (PDF) |
| 325 | Impact of Novel Agents on Young Patients with t(11;14) Multiple MyelomaBlood, 2014, 124, 2059-2059 | 4.2 | 1 | Citations (PDF) |
| 326 | Primary systemic amyloidosis | 4.2 | 17 | Citations (PDF) |
| 327 | Smoldering multiple myeloma requiring treatment: time for a new definition?Blood, 2013, 122, 4172-4181 | 4.2 | 77 | Citations (PDF) |
| 328 | Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies | 4.1 | 15 | Citations (PDF) |
| 329 | International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease | 21.6 | 324 | Citations (PDF) |
| 330 | Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels | 1.9 | 15 | Citations (PDF) |
| 331 | Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myelomaBlood, 2013, 121, 884-892 | 4.2 | 160 | Citations (PDF) |
| 332 | Monoclonal Gammopathy–Associated Proliferative Glomerulonephritis | 3.1 | 88 | Citations (PDF) |
| 333 | In reply | 3.1 | 0 | Citations (PDF) |
| 334 | Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 | 3.1 | 494 | Citations (PDF) |
| 335 | Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia | 1.0 | 19 | Citations (PDF) |
| 336 | Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management | 6.1 | 107 | Citations (PDF) |
| 337 | A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? | 4.1 | 51 | Citations (PDF) |
| 338 | IV. Initial treatment of multiple myeloma | 2.2 | 6 | Citations (PDF) |
| 339 | Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma | 1.9 | 3 | Citations (PDF) |
| 340 | Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approachBlood, 2013, 121, 3147-3152 | 4.2 | 60 | Citations (PDF) |
| 341 | Outcomes of patients with POEMS syndrome treated initially with radiation | 4.2 | 86 | Citations (PDF) |
| 342 | Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel AgentsBlood, 2013, 122, 3117-3117 | 4.2 | 2 | Citations (PDF) |
| 343 | Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology GroupBlood, 2013, 122, 3174-3174 | 4.2 | 2 | Citations (PDF) |
| 344 | Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple MyelomaBlood, 2013, 122, 3210-3210 | 4.2 | 9 | Citations (PDF) |
| 345 | Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized TrialsBlood, 2013, 122, 407-407 | 4.2 | 13 | Citations (PDF) |
| 346 | Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple MyelomaBlood, 2013, 122, 1979-1979 | 4.2 | 0 | Citations (PDF) |
| 347 | Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple MyelomaBlood, 2013, 122, 754-754 | 4.2 | 0 | Citations (PDF) |
| 348 | A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1Blood, 2013, 122, 3111-3111 | 4.2 | 2 | Citations (PDF) |
| 349 | Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression LevelsBlood, 2013, 122, 1962-1962 | 4.2 | 0 | Citations (PDF) |
| 350 | Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk MyelomaBlood, 2013, 122, 1842-1842 | 4.2 | 0 | Citations (PDF) |
| 351 | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood, 2012, 119, 4375-4382 | 4.2 | 431 | Citations (PDF) |
| 352 | Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities | 0.8 | 48 | Citations (PDF) |
| 353 | Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisBlood, 2012, 119, 5397-5404 | 4.2 | 155 | Citations (PDF) |
| 354 | Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy–Related Kidney Diseases | 4.4 | 82 | Citations (PDF) |
| 355 | Immunoglobulin D amyloidosis: a distinct entity | 4.2 | 18 | Citations (PDF) |
| 356 | High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementBlood, 2012, 119, 1117-1122 | 4.2 | 84 | Citations (PDF) |
| 357 | Progression in smoldering Waldenström macroglobulinemia: long-term resultsBlood, 2012, 119, 4462-4466 | 4.2 | 132 | Citations (PDF) |
| 358 | Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialBlood, 2012, 119, 4860-4867 | 4.2 | 124 | Citations (PDF) |
| 359 | Second to noneBlood, 2012, 120, 1537-1539 | 4.2 | 6 | Citations (PDF) |
| 360 | Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsBlood, 2012, 119, 2100-2105 | 4.2 | 239 | Citations (PDF) |
| 361 | Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population | 3.1 | 118 | Citations (PDF) |
| 362 | Bortezomib Combination Therapy in Multiple Myeloma | 3.2 | 70 | Citations (PDF) |
| 363 | Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition | 3.1 | 114 | Citations (PDF) |
| 364 | Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? | 2.9 | 30 | Citations (PDF) |
| 365 | Trends and outcomes of modern staging of solitary plasmacytoma of bone | 6.1 | 80 | Citations (PDF) |
| 366 | Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristicsBlood, 2012, 119, 5359-5366 | 4.2 | 76 | Citations (PDF) |
| 367 | Clonal competition with alternating dominance in multiple myelomaBlood, 2012, 120, 1067-1076 | 4.2 | 600 | Citations (PDF) |
| 368 | Elucidating disparities across racial and ethnic groups in multiple myeloma patients | 1.6 | 3 | Citations (PDF) |
| 369 | A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma | 2.4 | 51 | Citations (PDF) |
| 370 | Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies | 1.4 | 197 | Citations (PDF) |
| 371 | Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation | 1.9 | 12 | Citations (PDF) |
| 372 | Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma | 4.1 | 111 | Citations (PDF) |
| 373 | Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and management | 6.1 | 122 | Citations (PDF) |
| 374 | Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin | 6.1 | 29 | Citations (PDF) |
| 375 | Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple MyelomaBlood, 2012, 120, 194-194 | 4.2 | 11 | Citations (PDF) |
| 376 | Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 PatientsBlood, 2012, 120, 201-201 | 4.2 | 18 | Citations (PDF) |
| 377 | Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.Blood, 2012, 120, 3138-3138 | 4.2 | 29 | Citations (PDF) |
| 378 | Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel AgentsBlood, 2012, 120, 3972-3972 | 4.2 | 9 | Citations (PDF) |
| 379 | Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology GroupBlood, 2012, 120, 4079-4079 | 4.2 | 1 | Citations (PDF) |
| 380 | Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.Blood, 2012, 120, 946-946 | 4.2 | 1 | Citations (PDF) |
| 381 | Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway | 2.4 | 56 | Citations (PDF) |
| 382 | Upfront Therapy for Myeloma: Tailoring Therapy across the Disease Spectrum | 4.6 | 1 | Citations (PDF) |
| 383 | Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.Blood, 2012, 120, 2973-2973 | 4.2 | 16 | Citations (PDF) |
| 384 | Outcomes of Patients with POEMS Syndrome Treated Initially with RadiationBlood, 2012, 120, 448-448 | 4.2 | 0 | Citations (PDF) |
| 385 | A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Pre1003, a Precog LLC StudyBlood, 2012, 120, 1856-1856 | 4.2 | 7 | Citations (PDF) |
| 386 | Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.Blood, 2012, 120, 2948-2948 | 4.2 | 0 | Citations (PDF) |
| 387 | Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 PatientsBlood, 2012, 120, 934-934 | 4.2 | 0 | Citations (PDF) |
| 388 | Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.Blood, 2012, 120, 2943-2943 | 4.2 | 0 | Citations (PDF) |
| 389 | Promising Pre-Clinical Activity of A-1014907, a Dual Inhibitor of Aurora Kinases and VEGFR in Multiple MyelomaBlood, 2012, 120, 1848-1848 | 4.2 | 0 | Citations (PDF) |
| 390 | Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and PrognosisBlood, 2012, 120, 1861-1861 | 4.2 | 2 | Citations (PDF) |
| 391 | Treatment Trade-Offs in Myeloma: a Survey of Consecutive PatientsBlood, 2012, 120, 2059-2059 | 4.2 | 0 | Citations (PDF) |
| 392 | Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Blood, 2011, 117, 4701-4705 | 4.2 | 403 | Citations (PDF) |
| 393 | Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myelomaBlood, 2011, 118, 2985-2987 | 4.2 | 37 | Citations (PDF) |
| 394 | Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score | 3.1 | 182 | Citations (PDF) |
| 395 | Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney | 0.4 | 214 | Citations (PDF) |
| 396 | Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone | 1.0 | 59 | Citations (PDF) |
| 397 | IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström's Macroglobulinemia (SWM) | 1.0 | 41 | Citations (PDF) |
| 398 | Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future | 3.2 | 9 | Citations (PDF) |
| 399 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011, 117, 4691-4695 | 4.2 | 953 | Citations (PDF) |
| 400 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011, 117, 4696-4700 | 4.2 | 299 | Citations (PDF) |
| 401 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011, 117, 6063-6073 | 4.2 | 295 | Citations (PDF) |
| 402 | Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survivalBlood, 2011, 118, 2702-2707 | 4.2 | 24 | Citations (PDF) |
| 403 | Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneBlood, 2011, 118, 4359-4362 | 4.2 | 43 | Citations (PDF) |
| 404 | Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseBlood, 2011, 118, 2970-2975 | 4.2 | 201 | Citations (PDF) |
| 405 | Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaBlood, 2011, 118, 1763-1765 | 4.2 | 61 | Citations (PDF) |
| 406 | Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUSBlood, 2011, 118, 6529-6534 | 4.2 | 70 | Citations (PDF) |
| 407 | Approach to the treatment of multiple myeloma: a clash of philosophiesBlood, 2011, 118, 3205-3211 | 4.2 | 142 | Citations (PDF) |
| 408 | Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03 | 2.4 | 30 | Citations (PDF) |
| 409 | Initial genome sequencing and analysis of multiple myeloma | 38.7 | 1,350 | Citations (PDF) |
| 410 | Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature | 1.5 | 47 | Citations (PDF) |
| 411 | Update on risk stratification and treatment of newly diagnosed multiple myeloma | 1.6 | 33 | Citations (PDF) |
| 412 | Multiple myeloma: 2011 update on diagnosis, risk‐stratification, and management | 6.1 | 145 | Citations (PDF) |
| 413 | Changes in serum‐free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis | 6.1 | 81 | Citations (PDF) |
| 414 | High prevalence of polyclonal hypergamma‐globulinemia in adult males in Ghana, Africa | 6.1 | 16 | Citations (PDF) |
| 415 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial | 6.1 | 58 | Citations (PDF) |
| 416 | From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention | 6.9 | 77 | Citations (PDF) |
| 417 | Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies | 1.1 | 72 | Citations (PDF) |
| 418 | Treatment of multiple myeloma | 75.5 | 266 | Citations (PDF) |
| 419 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | 10.4 | 708 | Citations (PDF) |
| 420 | A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans | 1.1 | 9 | Citations (PDF) |
| 421 | Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 AnalysisBlood, 2011, 118, 1882-1882 | 4.2 | 2 | Citations (PDF) |
| 422 | The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain AmyloidosisBlood, 2011, 118, 2887-2887 | 4.2 | 1 | Citations (PDF) |
| 423 | Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original CohortBlood, 2011, 118, 2942-2942 | 4.2 | 2 | Citations (PDF) |
| 424 | Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel TherapiesBlood, 2011, 118, 2950-2950 | 4.2 | 1 | Citations (PDF) |
| 425 | Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,Blood, 2011, 118, 3963-3963 | 4.2 | 4 | Citations (PDF) |
| 426 | Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative ComponentBlood, 2011, 118, 2945-2945 | 4.2 | 2 | Citations (PDF) |
| 427 | The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL AmyloidosisBlood, 2011, 118, 2868-2868 | 4.2 | 8 | Citations (PDF) |
| 428 | Racial Disparities in Cytogenetic Characteristics and Outcome of Multiple MyelomaBlood, 2011, 118, 1808-1808 | 4.2 | 0 | Citations (PDF) |
| 429 | IgD Amyloidosis: An Unrecognized EntityBlood, 2011, 118, 5079-5079 | 4.2 | 0 | Citations (PDF) |
| 430 | Serum Free Light Chain Ratio in Distinguishing Smoldering Multiple Myeloma From Active Multiple Myeloma,Blood, 2011, 118, 3948-3948 | 4.2 | 0 | Citations (PDF) |
| 431 | Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,Blood, 2011, 118, 3989-3989 | 4.2 | 0 | Citations (PDF) |
| 432 | Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma,Blood, 2011, 118, 3980-3980 | 4.2 | 1 | Citations (PDF) |
| 433 | Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury,Blood, 2011, 118, 3949-3949 | 4.2 | 0 | Citations (PDF) |
| 434 | Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsBlood, 2010, 115, 1343-1350 | 4.2 | 119 | Citations (PDF) |
| 435 | Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenBlood, 2010, 116, 1056-1059 | 4.2 | 155 | Citations (PDF) |
| 436 | Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complicationsBlood, 2010, 116, 2019-2025 | 4.2 | 68 | Citations (PDF) |
| 437 | Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresBlood, 2010, 116, 5126-5129 | 4.2 | 160 | Citations (PDF) |
| 438 | Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma | 2.8 | 32 | Citations (PDF) |
| 439 | Multiple myeloma: chemotherapy or transplantation in the era of new drugs | 1.9 | 36 | Citations (PDF) |
| 440 | Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma | 1.9 | 8 | Citations (PDF) |
| 441 | Residual serum monoclonal protein predicts progression‐free survival in patients with previously untreated multiple myeloma | 4.1 | 3 | Citations (PDF) |
| 442 | Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome | 6.1 | 45 | Citations (PDF) |
| 443 | Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma | 6.1 | 49 | Citations (PDF) |
| 444 | Long‐term results of single‐agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma | 6.1 | 24 | Citations (PDF) |
| 445 | Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs | 6.1 | 119 | Citations (PDF) |
| 446 | How best to use new therapies in multiple myeloma | 5.2 | 12 | Citations (PDF) |
| 447 | Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma | 2.4 | 13 | Citations (PDF) |
| 448 | In Reply | 1.1 | 0 | Citations (PDF) |
| 449 | Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations | 21.6 | 106 | Citations (PDF) |
| 450 | Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma | 3.1 | 90 | Citations (PDF) |
| 451 | Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2 | 3.1 | 5 | Citations (PDF) |
| 452 | Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review | 3.1 | 210 | Citations (PDF) |
| 453 | Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group | 21.6 | 384 | Citations (PDF) |
| 454 | Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study | 52.8 | 359 | Citations (PDF) |
| 455 | Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | 26.0 | 928 | Citations (PDF) |
| 456 | Optimising bortezomib in newly diagnosed multiple myeloma | 26.0 | 6 | Citations (PDF) |
| 457 | Higher Plasma Cell Burden Predicts for Early Death In Patients with AL AmyloidosisBlood, 2010, 116, 1893-1893 | 4.2 | 1 | Citations (PDF) |
| 458 | Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple MyelomaBlood, 2010, 116, 1964-1964 | 4.2 | 5 | Citations (PDF) |
| 459 | A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289)Blood, 2010, 116, 3053-3053 | 4.2 | 1 | Citations (PDF) |
| 460 | Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)Blood, 2010, 116, 308-308 | 4.2 | 8 | Citations (PDF) |
| 461 | Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) AmyloidosisBlood, 2010, 116, 370-370 | 4.2 | 4 | Citations (PDF) |
| 462 | Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial | 4.2 | 17 | Citations (PDF) |
| 463 | Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall SurvivalBlood, 2010, 116, 3893-3893 | 4.2 | 2 | Citations (PDF) |
| 464 | Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION StudyBlood, 2010, 116, 621-621 | 4.2 | 15 | Citations (PDF) |
| 465 | Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory DiseaseBlood, 2010, 116, 863-863 | 4.2 | 1 | Citations (PDF) |
| 466 | Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple MyelomaBlood, 2010, 116, 4048-4048 | 4.2 | 0 | Citations (PDF) |
| 467 | Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide TherapyBlood, 2010, 116, 1965-1965 | 4.2 | 0 | Citations (PDF) |
| 468 | Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary DiseaseBlood, 2010, 116, 3047-3047 | 4.2 | 0 | Citations (PDF) |
| 469 | A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) AmyloidosisBlood, 2010, 116, 987-987 | 4.2 | 1 | Citations (PDF) |
| 470 | Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell LinesBlood, 2010, 116, 3014-3014 | 4.2 | 1 | Citations (PDF) |
| 471 | Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple MyelomaBlood, 2010, 116, 4078-4078 | 4.2 | 0 | Citations (PDF) |
| 472 | Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple MyelomaBlood, 2010, 116, 2998-2998 | 4.2 | 0 | Citations (PDF) |
| 473 | Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009, 113, 5412-5417 | 4.2 | 1,041 | Citations (PDF) |
| 474 | Screening Panels for Detection of Monoclonal Gammopathies | 1.1 | 308 | Citations (PDF) |
| 475 | Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney | 0.8 | 118 | Citations (PDF) |
| 476 | Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma | 6.1 | 67 | Citations (PDF) |
| 477 | Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival | 6.1 | 88 | Citations (PDF) |
| 478 | The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high‐dose cyclophosphamide and α<sub>2</sub>β interferon versus VBMCP | 4.1 | 9 | Citations (PDF) |
| 479 | Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia | 7.1 | 63 | Citations (PDF) |
| 480 | Multiple Myeloma | 2.0 | 69 | Citations (PDF) |
| 481 | Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group | 0.7 | 54 | Citations (PDF) |
| 482 | Treatment of Multiple Myeloma: A Comprehensive Review | 1.9 | 144 | Citations (PDF) |
| 483 | Front-Line Treatment in Younger Patients With Multiple Myeloma | 3.2 | 19 | Citations (PDF) |
| 484 | Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients | 3.1 | 185 | Citations (PDF) |
| 485 | Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines | 3.1 | 416 | Citations (PDF) |
| 486 | Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component | 3.1 | 247 | Citations (PDF) |
| 487 | Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health StudyBlood, 2009, 113, 6386-6391 | 4.2 | 150 | Citations (PDF) |
| 488 | Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyBlood, 2009, 114, 4928-4932 | 4.2 | 79 | Citations (PDF) |
| 489 | Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceBlood, 2009, 114, 785-790 | 4.2 | 140 | Citations (PDF) |
| 490 | Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis | 4.1 | 103 | Citations (PDF) |
| 491 | Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.Blood, 2009, 114, 127-127 | 4.2 | 19 | Citations (PDF) |
| 492 | Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.Blood, 2009, 114, 2868-2868 | 4.2 | 3 | Citations (PDF) |
| 493 | A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.Blood, 2009, 114, 3853-3853 | 4.2 | 8 | Citations (PDF) |
| 494 | Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.Blood, 2009, 114, 615-615 | 4.2 | 6 | Citations (PDF) |
| 495 | Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.Blood, 2009, 114, 956-956 | 4.2 | 1 | Citations (PDF) |
| 496 | Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.Blood, 2009, 114, 2877-2877 | 4.2 | 0 | Citations (PDF) |
| 497 | Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.Blood, 2009, 114, 3884-3884 | 4.2 | 0 | Citations (PDF) |
| 498 | Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma.Blood, 2009, 114, 2803-2803 | 4.2 | 0 | Citations (PDF) |
| 499 | Thromboembolic events with lenalidomide‐based therapy for multiple myeloma | 4.1 | 83 | Citations (PDF) |
| 500 | Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis | 6.1 | 124 | Citations (PDF) |
| 501 | Anti‐CD20 monoclonal antibody therapy in multiple myeloma | 2.4 | 103 | Citations (PDF) |
| 502 | Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders | 2.4 | 21 | Citations (PDF) |
| 503 | The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma | 2.4 | 95 | Citations (PDF) |
| 504 | Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma | 2.4 | 95 | Citations (PDF) |
| 505 | R-(-)−gossypol (AT-101) activates programmed cell death in multiple myeloma cells | 0.4 | 60 | Citations (PDF) |
| 506 | Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial | 1.9 | 13 | Citations (PDF) |
| 507 | Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance–reply–I | 3.1 | 0 | Citations (PDF) |
| 508 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood, 2008, 112, 4445-4451 | 4.2 | 168 | Citations (PDF) |
| 509 | Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy | 1.2 | 126 | Citations (PDF) |
| 510 | Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis | 3.1 | 45 | Citations (PDF) |
| 511 | Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008, 111, 2516-2520 | 4.2 | 2,120 | Citations (PDF) |
| 512 | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma | 21.6 | 335 | Citations (PDF) |
| 513 | Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance–reply–I | 3.1 | 1 | Citations (PDF) |
| 514 | Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008, 111, 785-789 | 4.2 | 396 | Citations (PDF) |
| 515 | Multiple myelomaBlood, 2008, 111, 2962-2972 | 4.2 | 878 | Citations (PDF) |
| 516 | Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingBlood, 2008, 112, 4924-4934 | 4.2 | 64 | Citations (PDF) |
| 517 | Many facets of bortezomib resistance/susceptibilityBlood, 2008, 112, 2177-2178 | 4.2 | 76 | Citations (PDF) |
| 518 | Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.Blood, 2008, 112, 1663-1663 | 4.2 | 1 | Citations (PDF) |
| 519 | Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex).Blood, 2008, 112, 1729-1729 | 4.2 | 2 | Citations (PDF) |
| 520 | Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).Blood, 2008, 112, 1740-1740 | 4.2 | 5 | Citations (PDF) |
| 521 | Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaBlood, 2008, 112, 3467-3467 | 4.2 | 2 | Citations (PDF) |
| 522 | Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple MyelomaBlood, 2008, 112, 3702-3702 | 4.2 | 6 | Citations (PDF) |
| 523 | TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s MacroglobulinemiaBlood, 2008, 112, 619-619 | 4.2 | 6 | Citations (PDF) |
| 524 | Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple MyelomaBlood, 2008, 112, 866-866 | 4.2 | 26 | Citations (PDF) |
| 525 | Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma | 4.2 | 8 | Citations (PDF) |
| 526 | Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study | 4.2 | 17 | Citations (PDF) |
| 527 | Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome | 4.2 | 3 | Citations (PDF) |
| 528 | Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.Blood, 2008, 112, 1707-1707 | 4.2 | 0 | Citations (PDF) |
| 529 | Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical FeaturesBlood, 2008, 112, 2733-2733 | 4.2 | 0 | Citations (PDF) |
| 530 | Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell TransplantationBlood, 2008, 112, 2769-2769 | 4.2 | 0 | Citations (PDF) |
| 531 | Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstrom’s MacroglobulinemiaBlood, 2008, 112, 2709-2709 | 4.2 | 6 | Citations (PDF) |
| 532 | The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on OutcomeBlood, 2008, 112, 5114-5114 | 4.2 | 0 | Citations (PDF) |
| 533 | Comparison of Bromcresol Green and Agarose Protein Electrophoresis for Quantitation of Serum Albumin in Multiple Myeloma | 1.1 | 36 | Citations (PDF) |
| 534 | Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma | 6.9 | 71 | Citations (PDF) |
| 535 | The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2007, 109, 465-470 | 4.2 | 269 | Citations (PDF) |
| 536 | Cancer Symposium for the Practitioner: Introduction to Solid Tumors | 3.1 | 7 | Citations (PDF) |
| 537 | Epidemiology of the plasma-cell disorders | 1.8 | 122 | Citations (PDF) |
| 538 | Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana | 3.1 | 167 | Citations (PDF) |
| 539 | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma | 43.7 | 853 | Citations (PDF) |
| 540 | Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma | 2.3 | 50 | Citations (PDF) |
| 541 | Management of Newly Diagnosed Myeloma | 2.3 | 14 | Citations (PDF) |
| 542 | Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement–Reply–I | 3.1 | 12 | Citations (PDF) |
| 543 | Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma | 3.1 | 143 | Citations (PDF) |
| 544 | Cancer Symposium for the Practitioner: Introduction to Solid Tumors | 3.1 | 10 | Citations (PDF) |
| 545 | Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America | 43.7 | 1,208 | Citations (PDF) |
| 546 | Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation | 1.8 | 43 | Citations (PDF) |
| 547 | Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma | 5.2 | 59 | Citations (PDF) |
| 548 | Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression | 0.7 | 61 | Citations (PDF) |
| 549 | Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression | 2.4 | 106 | Citations (PDF) |
| 550 | Renal Manifestations of Plasma Cell Disorders | 1.4 | 35 | Citations (PDF) |
| 551 | Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.Blood, 2007, 110, 1487-1487 | 4.2 | 3 | Citations (PDF) |
| 552 | Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.Blood, 2007, 110, 190-190 | 4.2 | 7 | Citations (PDF) |
| 553 | Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).Blood, 2007, 110, 241-241 | 4.2 | 1 | Citations (PDF) |
| 554 | Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition.Blood, 2007, 110, 246-246 | 4.2 | 4 | Citations (PDF) |
| 555 | A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.Blood, 2007, 110, 3601-3601 | 4.2 | 4 | Citations (PDF) |
| 556 | A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. | 4.2 | 58 | Citations (PDF) |
| 557 | Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?.Blood, 2007, 110, 939-939 | 4.2 | 1 | Citations (PDF) |
| 558 | Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.Blood, 2007, 110, 3608-3608 | 4.2 | 0 | Citations (PDF) |
| 559 | Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00).Blood, 2007, 110, 2734-2734 | 4.2 | 1 | Citations (PDF) |
| 560 | Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.Blood, 2007, 110, 659-659 | 4.2 | 0 | Citations (PDF) |
| 561 | Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceeding Plasma Cell Disorders.Blood, 2007, 110, 945-945 | 4.2 | 0 | Citations (PDF) |
| 562 | Recurrent Infections in Multiple Myeloma–Reply–I | 3.1 | 0 | Citations (PDF) |
| 563 | Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment | 3.1 | 191 | Citations (PDF) |
| 564 | Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy | 3.1 | 79 | Citations (PDF) |
| 565 | Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays | 3.1 | 202 | Citations (PDF) |
| 566 | Response to Rituximab in Patients with Type II Cryoglobulinemia | 1.9 | 35 | Citations (PDF) |
| 567 | Prevalence of Monoclonal Gammopathy of Undetermined Significance | 43.7 | 1,297 | Citations (PDF) |
| 568 | Thalidomide and lenalidomide in the treatment of multiple myeloma | 5.1 | 115 | Citations (PDF) |
| 569 | Dermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma | 1.6 | 79 | Citations (PDF) |
| 570 | Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2006, 107, 3378-3383 | 4.2 | 241 | Citations (PDF) |
| 571 | Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemBlood, 2006, 107, 3384-3388 | 4.2 | 72 | Citations (PDF) |
| 572 | Clinical implication of centrosome amplification in plasma cell neoplasmBlood, 2006, 107, 3669-3675 | 4.2 | 90 | Citations (PDF) |
| 573 | Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006, 108, 1979-1983 | 4.2 | 161 | Citations (PDF) |
| 574 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006, 108, 3458-3464 | 4.2 | 507 | Citations (PDF) |
| 575 | Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia | 2.4 | 132 | Citations (PDF) |
| 576 | Monoclonal gammopathy of undetermined significance | 2.4 | 213 | Citations (PDF) |
| 577 | 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance | 1.3 | 109 | Citations (PDF) |
| 578 | Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: | 4.1 | 137 | Citations (PDF) |
| 579 | Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib | 21.6 | 612 | Citations (PDF) |
| 580 | A phase II trial of imatinib in patients with refractory/relapsed myeloma | 1.5 | 44 | Citations (PDF) |
| 581 | Natural history of thromboembolism in AL amyloidosis | 4.7 | 32 | Citations (PDF) |
| 582 | Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group | 21.6 | 820 | Citations (PDF) |
| 583 | Fracture Risk With Multiple Myeloma: A Population-Based Study | 5.0 | 300 | Citations (PDF) |
| 584 | MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management | 2.9 | 84 | Citations (PDF) |
| 585 | Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaBlood, 2005, 106, 2977-2981 | 4.2 | 108 | Citations (PDF) |
| 586 | Multiple myeloma: the death of VAD as initial therapy | 4.2 | 25 | Citations (PDF) |
| 587 | Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myelomaBlood, 2005, 106, 2276-2279 | 4.2 | 228 | Citations (PDF) |
| 588 | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005, 106, 4050-4053 | 4.2 | 625 | Citations (PDF) |
| 589 | Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation | 1.6 | 62 | Citations (PDF) |
| 590 | Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma | 4.1 | 99 | Citations (PDF) |
| 591 | Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance | 21.6 | 120 | Citations (PDF) |
| 592 | Thalidomide and dexamethasone: therapy for multiple myeloma | 2.6 | 22 | Citations (PDF) |
| 593 | Multiple Myeloma: Diagnosis and Treatment | 3.1 | 213 | Citations (PDF) |
| 594 | Introduction to a Cancer Symposium for the Practitioner | 3.1 | 7 | Citations (PDF) |
| 595 | Prognostic Factors and Predictors of Outcome of Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance | 1.9 | 22 | Citations (PDF) |
| 596 | Monoclonal Gammopathy of Undetermined Significance | 1.9 | 42 | Citations (PDF) |
| 597 | Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer | 21.6 | 537 | Citations (PDF) |
| 598 | Conventional therapy and approach to management | 1.8 | 6 | Citations (PDF) |
| 599 | Monoclonal gammopathies of undetermined significance | 1.8 | 34 | Citations (PDF) |
| 600 | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005, 106, 812-817 | 4.2 | 640 | Citations (PDF) |
| 601 | Fracture Risk in Monoclonal Gammopathy of Undetermined Significance | 5.0 | 155 | Citations (PDF) |
| 602 | Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis | 21.6 | 897 | Citations (PDF) |
| 603 | Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies | 21.6 | 88 | Citations (PDF) |
| 604 | Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance | 2.4 | 63 | Citations (PDF) |
| 605 | Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments | 6.1 | 26 | Citations (PDF) |
| 606 | Incidence of multiple myeloma in Olmsted County, Minnesota | 4.1 | 194 | Citations (PDF) |
| 607 | Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later | 3.1 | 177 | Citations (PDF) |
| 608 | Clinical Course of Patients With Relapsed Multiple Myeloma | 3.1 | 351 | Citations (PDF) |
| 609 | Multiple Myeloma | 43.7 | 1,356 | Citations (PDF) |
| 610 | Identification of genes modulated in multiple myeloma using genetically identical twin samplesBlood, 2004, 103, 1799-1806 | 4.2 | 129 | Citations (PDF) |
| 611 | Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2004, 104, 1881-1887 | 4.2 | 316 | Citations (PDF) |
| 612 | Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma | 4.2 | 137 | Citations (PDF) |
| 613 | Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionBlood, 2004, 104, 1159-1165 | 4.2 | 137 | Citations (PDF) |
| 614 | Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyBlood, 2004, 103, 3960-3963 | 4.2 | 232 | Citations (PDF) |
| 615 | Angiogenesis in Waldenstrom's macroglobulinemia | 1.9 | 16 | Citations (PDF) |
| 616 | Influence of postoperative acute-phase responseon angiogenesis and tumor growth: open vs. laparoscopic-assisted surgery in mice | 1.9 | 52 | Citations (PDF) |
| 617 | Monoclonal gammopathies of undetermined significance: a review | 6.6 | 118 | Citations (PDF) |
| 618 | Bone marrow angiogenesis and circulating plasma cells in multiple myeloma | 2.4 | 24 | Citations (PDF) |
| 619 | Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2.4 | 31 | Citations (PDF) |
| 620 | Use of Bisphosphonates in Patients With Myeloma and Renal Failure–Reply–I | 3.1 | 1 | Citations (PDF) |
| 621 | Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma | 3.1 | 124 | Citations (PDF) |
| 622 | Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 3.2 | 12 | Citations (PDF) |
| 623 | Review of 1027 Patients With Newly Diagnosed Multiple Myeloma | 3.1 | 2,122 | Citations (PDF) |
| 624 | POEMS syndrome: definitions and long-term outcomeBlood, 2003, 101, 2496-2506 | 4.2 | 747 | Citations (PDF) |
| 625 | A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | 43.7 | 2,527 | Citations (PDF) |
| 626 | Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | 4.7 | 130 | Citations (PDF) |
| 627 | Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisBlood, 2003, 101, 827-830 | 4.2 | 74 | Citations (PDF) |
| 628 | Prognostic value of angiogenesis in solitary bone plasmacytomaBlood, 2003, 101, 1715-1717 | 4.2 | 107 | Citations (PDF) |
| 629 | Long-term follow-up of IgM monoclonal gammopathy of undetermined significanceBlood, 2003, 102, 3759-3764 | 4.2 | 298 | Citations (PDF) |
| 630 | A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies | 1.9 | 35 | Citations (PDF) |
| 631 | Thrombotic Thrombocytopenic Purpura Associated with a Hepatic Abscess Due toActinomyces turicensis | 5.4 | 25 | Citations (PDF) |
| 632 | Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemiaBlood, 2002, 99, 4131-4137 | 4.2 | 60 | Citations (PDF) |
| 633 | A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance | 43.7 | 1,428 | Citations (PDF) |
| 634 | Current Therapy for Multiple Myeloma | 3.1 | 101 | Citations (PDF) |
| 635 | Thalidomide-Induced Neuropathy: In Response | 3.1 | 2 | Citations (PDF) |
| 636 | Genomic abnormalities in monoclonal gammopathy of undetermined significanceBlood, 2002, 100, 1417-1424 | 4.2 | 329 | Citations (PDF) |
| 637 | Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression | 1.3 | 58 | Citations (PDF) |
| 638 | MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE | 1.7 | 26 | Citations (PDF) |
| 639 | Bone marrow angiogenesis in multiple myeloma: effect of therapy | 2.4 | 49 | Citations (PDF) |
| 640 | <i>Helicobacter pylori</i> infection and monoclonal gammopathy of undetermined significance | 2.4 | 32 | Citations (PDF) |
| 641 | Myeloma and the newly diagnosed patient: A focus on treatment and management | 1.9 | 87 | Citations (PDF) |
| 642 | Angiogenesis in multiple myeloma | 2.4 | 13 | Citations (PDF) |
| 643 | Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation | 6.1 | 63 | Citations (PDF) |
| 644 | Thalidomide in the treatment of multiple myeloma | 2.6 | 20 | Citations (PDF) |
| 645 | Therapeutic application of thalidomide in multiple myeloma | 1.9 | 15 | Citations (PDF) |
| 646 | Angiogenesis in multiple myeloma | 1.9 | 5 | Citations (PDF) |
| 647 | Title is missing! | 2.6 | 11 | Citations (PDF) |
| 648 | FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis | 1.5 | 11 | Citations (PDF) |
| 649 | Waldenström's Macroglobulinemia | 3.5 | 110 | Citations (PDF) |
| 650 | Thalidomide in the Treatment of Relapsed Multiple Myeloma | 3.1 | 174 | Citations (PDF) |
| 651 | Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasiaBlood, 2000, 96, 3374-3380 | 4.2 | 156 | Citations (PDF) |
| 652 | Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma | 21.6 | 66 | Citations (PDF) |
| 653 | Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas | 1.9 | 21 | Citations (PDF) |
| 654 | Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma | 1.5 | 32 | Citations (PDF) |
| 655 | PROGNOSTIC FACTORS IN MULTIPLE MYELOMA | 2.3 | 99 | Citations (PDF) |
| 656 | MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE | 2.3 | 85 | Citations (PDF) |
| 657 | Screening Mammography in Women Aged 40-49 Years | 1.3 | 10 | Citations (PDF) |
| 658 | Phase II North Central Cancer Treatment Group Study of 2-Chlorodeoxyadenosine in Patients With Recurrent Glioma | 1.3 | 11 | Citations (PDF) |
| 659 | Primary systemic amyloidosis with delayed progression to multiple myeloma 1998, 82, 1501-1505 | | 115 | Citations (PDF) |
| 660 | Anemia After Orchiectomy | 6.1 | 62 | Citations (PDF) |
| 661 | Diagnostic Value of Albumin Gene Expression in Liver Tumors: Case Report and Review of the Literature | 3.1 | 10 | Citations (PDF) |
| 662 | Granulomatous Vasculitis Associated With Herpes Virus | 3.1 | 0 | Citations (PDF) |
| 663 | Combination Chemotherapy with Cisplatin, Carboplatin, and Etoposide in Advanced Malignancy | 1.3 | 3 | Citations (PDF) |
| 664 | Number needed to treat is a simple measure of treatment efficacy for clinicians | 2.8 | 27 | Citations (PDF) |
| 665 | A classic case of amyloid cardiomyopathy | 0.4 | 1 | Citations (PDF) |
| 666 | Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care | 3.0 | 6 | Citations (PDF) |
